Comparison 6. Gefitinib versus chemotherapy (EGFR mutation).

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 HR Overall survival = 1st line	5		Hazard Ratio (Fixed, 95% CI)	0.97 [0.77, 1.21]
1.1 Biomarker driven selection	2		Hazard Ratio (Fixed, 95% CI)	0.98 [0.72, 1.33]
1.2 Clinical feature driven selection	3		Hazard Ratio (Fixed, 95% CI)	0.95 [0.68, 1.33]
2 HR Overall survival = 2nd line	1		Hazard Ratio (Fixed, 95% CI)	0.83 [0.41, 1.66]
2.1 G vs docetaxel	1		Hazard Ratio (Fixed, 95% CI)	0.83 [0.41, 1.66]
3 HR Progression‐free survival = 1st line	5		Hazard Ratio (Random, 95% CI)	0.47 [0.36, 0.61]
3.1 Biomarker driven selection	2		Hazard Ratio (Random, 95% CI)	0.39 [0.26, 0.59]
3.2 Clinical feature driven selection	3		Hazard Ratio (Random, 95% CI)	0.53 [0.41, 0.70]
4 HR Progression‐free survival = 2nd line	2		Hazard Ratio (Fixed, 95% CI)	0.24 [0.12, 0.47]
4.1 G vs docetaxel	1		Hazard Ratio (Fixed, 95% CI)	0.16 [0.05, 0.50]
4.2 G vs pemetrexed	1		Hazard Ratio (Fixed, 95% CI)	0.30 [0.13, 0.70]
5 Overall response rate	7	758	Risk Ratio (M‐H, Random, 95% CI)	1.71 [1.34, 2.19]
5.1 First‐line biomarker driven selection	2	347	Risk Ratio (M‐H, Random, 95% CI)	2.23 [1.75, 2.85]
5.2 First‐line, clinical feature driven selection	3	353	Risk Ratio (M‐H, Random, 95% CI)	1.45 [1.05, 1.99]
5.3 2nd line	2	58	Risk Ratio (M‐H, Random, 95% CI)	1.65 [0.88, 3.09]
6 Stable disease	3	397	Risk Ratio (M‐H, Random, 95% CI)	0.52 [0.28, 0.97]
6.1 First‐line, biomarker driven selection	2	347	Risk Ratio (M‐H, Random, 95% CI)	0.47 [0.22, 0.98]
6.2 First‐line, clinical feature driven selection	1	50	Risk Ratio (M‐H, Random, 95% CI)	0.87 [0.26, 2.85]
7 Disease control rate	5	2001	Risk Ratio (M‐H, Random, 95% CI)	1.05 [0.93, 1.19]
7.1 First‐line, biomarker driven selection	2	347	Risk Ratio (M‐H, Random, 95% CI)	1.15 [1.05, 1.26]
7.2 First‐line, clinical feature driven selection	2	1267	Risk Ratio (M‐H, Random, 95% CI)	0.93 [0.87, 0.99]
7.3 Second‐line	1	387	Risk Ratio (M‐H, Random, 95% CI)	1.03 [0.77, 1.36]